Numerai GP LLC Buys Shares of 15,724 Pacira BioSciences, Inc. (NASDAQ:PCRX)

Numerai GP LLC bought a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX) in the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 15,724 shares of the company’s stock, valued at approximately $296,000.

Several other institutional investors have also modified their holdings of the stock. Renaissance Technologies LLC raised its stake in Pacira BioSciences by 0.7% during the fourth quarter. Renaissance Technologies LLC now owns 1,992,601 shares of the company’s stock worth $37,541,000 after purchasing an additional 13,604 shares during the period. Geode Capital Management LLC increased its holdings in shares of Pacira BioSciences by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 1,091,970 shares of the company’s stock worth $20,578,000 after buying an additional 5,071 shares during the last quarter. Northern Trust Corp raised its position in shares of Pacira BioSciences by 30.8% during the 4th quarter. Northern Trust Corp now owns 616,891 shares of the company’s stock valued at $11,622,000 after buying an additional 145,205 shares during the period. Impax Asset Management Group plc lifted its holdings in Pacira BioSciences by 14.8% in the fourth quarter. Impax Asset Management Group plc now owns 540,027 shares of the company’s stock valued at $10,174,000 after acquiring an additional 69,424 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Pacira BioSciences by 16.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 502,204 shares of the company’s stock worth $9,462,000 after acquiring an additional 70,307 shares during the period. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Trading Up 4.7%

NASDAQ PCRX opened at $25.60 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of -12.61 and a beta of 0.56. The firm has a 50 day simple moving average of $24.83 and a 200-day simple moving average of $22.31. Pacira BioSciences, Inc. has a one year low of $11.16 and a one year high of $31.67.

Analyst Ratings Changes

PCRX has been the topic of a number of research analyst reports. Barclays lifted their target price on Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a research report on Friday, February 28th. HC Wainwright boosted their price objective on shares of Pacira BioSciences from $48.00 to $65.00 and gave the company a “buy” rating in a report on Tuesday, April 8th. Needham & Company LLC lowered their target price on shares of Pacira BioSciences from $32.00 to $30.00 and set a “buy” rating for the company in a research note on Friday, May 9th. Finally, Truist Financial raised shares of Pacira BioSciences from a “sell” rating to a “hold” rating and boosted their price target for the company from $8.00 to $25.00 in a research note on Thursday, January 30th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $26.44.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.